Group One Trading’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$39.9M Buy
784,600
+40,800
+5% +$1.9M 0.08% 244
2025
Q4
$21.9M Buy
743,800
+106,500
+17% +$2.89M 0.04% 492
2025
Q3
$16.5M Buy
637,300
+211,400
+50% +$5.9M 0.03% 589
2025
Q2
$11.8M Sell
425,900
-121,100
-22% -$3.19M 0.03% 708
2025
Q1
$15.5M Buy
547,000
+293,200
+116% +$10.4M 0.05% 414
2024
Q4
$10.6M Buy
253,800
+130,000
+105% +$6.21M 0.02% 667
2024
Q3
$8.27M Buy
123,800
+39,300
+47% +$3.61M 0.02% 709
2024
Q2
$10M Buy
84,500
+8,900
+12% +$1.13M 0.04% 445
2024
Q1
$8.06M Sell
75,600
-128,500
-63% -$13M 0.03% 545
2023
Q4
$20.3M Buy
204,100
+70,100
+52% +$5.9M 0.05% 343
2023
Q3
$13.8M Buy
134,000
+24,800
+23% +$2.77M 0.05% 360
2023
Q2
$13.3M Sell
109,200
-17,800
-14% -$2.37M 0.04% 383
2023
Q1
$19.5M Sell
127,000
-1,044,000
-89% -$172M 0.07% 218
2022
Q4
$210M Buy
1,171,000
+143,900
+14% +$23.5M 0.49% 18
2022
Q3
$121M Sell
1,027,100
-748,400
-42% -$114M 0.24% 41
2022
Q2
$254M Sell
1,775,500
-224,600
-11% -$32.1M 0.4% 22
2022
Q1
$345M Buy
2,000,100
+164,300
+9% +$27.7M 0.34% 25
2021
Q4
$466M Buy
1,835,800
+283,700
+18% +$82.9M 0.37% 25
2021
Q3
$597M Buy
1,552,100
+792,400
+104% +$292M 0.65% 13
2021
Q2
$179M Buy
759,700
+232,700
+44% +$41.6M 0.22% 53
2021
Q1
$69M Sell
527,000
-355,300
-40% -$51.5M 0.1% 148
2020
Q4
$92.2M Buy
882,300
+204,300
+30% +$20.7M 0.16% 74
2020
Q3
$48M Buy
678,000
+231,000
+52% +$16.1M 0.15% 99
2020
Q2
$28.7M Sell
447,000
-120,100
-21% -$6.58M 0.13% 137
2020
Q1
$17M Buy
567,100
+231,400
+69% +$5.32M 0.14% 135
2019
Q4
$6.57M Buy
335,700
+230,700
+220% +$4.09M 0.04% 526
2019
Q3
$1.67M Buy
105,000
+13,400
+15% +$198K 0.01% 1343
2019
Q2
$1.34M Buy
91,600
+75,000
+452% +$1.61M 0.01% 1381
2019
Q1
$338K Buy
16,600
+15,200
+1,086% +$282K ﹤0.01% 2263
2018
Q4
$21K Buy
+1,400
New +$23K ﹤0.01% 4004

Other funds holding MRNA

Group One Trading's MRNA Position: Q1 2026 in Review

Group One Trading reduced its Moderna (MRNA) stake by 75% in Q1 2026, selling an estimated $6.63M and leaving 47,901 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Group One Trading first reported a position in MRNA in Q4 2018 and has held it in 25 quarters since. The position peaked at $37.3M in Q4 2022. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Group One Trading held 47,901 shares of Moderna worth $2.43M as of Q1 2026.
  • Group One Trading sold 142,054 Moderna shares in Q1 2026, an estimated $6.63M.
  • Moderna made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #1902 holding.
  • Group One Trading first reported a position in Moderna in Q4 2018 and has held it in 25 quarters since.
  • Group One Trading's Moderna position peaked at $37.3M in Q4 2022.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.